| abstract |
Use of a compound which formula (II): or a pharmaceutically acceptable salt, ester or amide thereof, in the manufacture of a medicament for the treatment of conditions which require the inhibition of an enzyme whose preferred mode of action is to catalyze the hydrolysis of an ester functionality, the condition being obesity or an obesity-related disorder, where in formula (II): R 1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or substituted derivative of one of the abovementioned groups, the substituents independently of one another being halogen, alkyl, halogen-substituted alkyl, aryl, arylalkyl, heteroaryl, reduced heteroaryl, reduced heteroarylalkyl, arylalkoxy, cyano, nitro, -C (O) R 4 , -CO 2 R 5 , -SOR 4 , -SO 2 R 4 , -NR 6 R 7 , -OR 6 , -SR 6 , -C (O) CX 1 X 2 NR 6 R 7 , -C (O) N (OH) R 6 , -C (O) NR 5 R 4 , -NR 6 C (O) R 4 , -CR 6 (NH 2 ) CO 2 R 6 , -NHCX 1 X 2 CO 2 R 6 , -N (OH) C (O NR 6 R 7 , -N (OH) C (O) R 4 , -NHC (O) NR 6 R 7 , -C (O) NHNR 6 R 7 or -C (O) N (OR 5 ) R 6 are ... |